Marc Peschanski
Overview
Explore the profile of Marc Peschanski including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
102
Citations
2572
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
31.
Turner M, Leslie S, Martin N, Peschanski M, Rao M, Taylor C, et al.
Cell Stem Cell
. 2013 Oct;
13(4):382-4.
PMID: 24094319
The ability to preselect the donor genotype of iPSC lines provides important opportunities for immune matching in cell therapy. Here we propose that an international assessment should be made of...
32.
Benchoua A, Peschanski M
Front Cell Neurosci
. 2013 Aug;
7:140.
PMID: 23986659
As fine regulators of gene expression, non-coding RNAs, and more particularly micro-RNAs (miRNAs), have emerged as key players in the development of the nervous system. In vivo experiments manipulating miRNAs...
33.
Gauthier M, Marteyn A, Denis J, Cailleret M, Giraud-Triboult K, Aubert S, et al.
Hum Mol Genet
. 2013 Aug;
22(25):5188-98.
PMID: 23922231
Myotonic dystrophy type 1 (DM1) is an RNA-mediated disorder caused by a non-coding CTG repeat expansion that, in particular, provokes functional alteration of CUG-binding proteins. As a consequence, several genes...
34.
Nicoleau C, Varela C, Bonnefond C, Maury Y, Bugi A, Aubry L, et al.
Stem Cells
. 2013 Jul;
31(9):1763-74.
PMID: 23818270
Wnt-ligands are among key morphogens that mediate patterning of the anterior territories of the developing brain in mammals. We qualified the role of Wnt-signals in regional specification and subregional organization...
35.
Charbord J, Poydenot P, Bonnefond C, Feyeux M, Casagrande F, Brinon B, et al.
Stem Cells
. 2013 May;
31(9):1816-28.
PMID: 23712629
Decreased expression of neuronal genes such as brain-derived neurotrophic factor (BDNF) is associated with several neurological disorders. One molecular mechanism associated with Huntington disease (HD) is a discrete increase in...
36.
Nedelec S, Onteniente B, Peschanski M, Martinat C
Curr Gene Ther
. 2013 Mar;
13(2):111-9.
PMID: 23444870
The fundamental inaccessibility of the human neural cell types affected by neurological disorders prevents their isolation for in vitro studies of disease mechanisms or for drug screening efforts. Pluripotent stem...
37.
Denis J, Gauthier M, Rachdi L, Aubert S, Giraud-Triboult K, Poydenot P, et al.
J Cell Sci
. 2013 Feb;
126(Pt 8):1763-72.
PMID: 23444380
Patients with myotonic dystrophy type 1 exhibit a diversity of symptoms that affect many different organs. Among these are cognitive dysfunctions, the origin of which has remained elusive, partly because...
38.
Perrier A, Peschanski M
Cell Stem Cell
. 2012 Aug;
11(2):153-61.
PMID: 22862942
Pluripotent stem cell (PSC) technologies are becoming a key asset for deciphering pathological cascades and for developing new treatments against many neurodegenerative disorders, including Huntington's disease (HD). This perspective discusses...
39.
Nissan X, Blondel S, Navarro C, Maury Y, Denis C, Girard M, et al.
Cell Rep
. 2012 Jul;
2(1):1-9.
PMID: 22840390
One puzzling observation in patients affected with Hutchinson-Gilford progeria syndrome (HGPS), who overall exhibit systemic and dramatic premature aging, is the absence of any conspicuous cognitive impairment. Recent studies based...
40.
Blondel S, Navarro C, Levy N, Peschanski M, Nissan X
Med Sci (Paris)
. 2012 Jul;
28(6-7):663-6.
PMID: 22805145
No abstract available.